Inhibition of the kit ligand/c-kit axis attenuates metastasis in a mouse model mimicking local breast cancer relapse after radiotherapy

Clinical Cancer Research

Volumn 18, Issue 16, 2012, Pages 4365-4374

  Kuonen, François ^a   Laurent, Julien ^a,e   Secondini, Chiara ^c   Lorusso, Girieca ^a,b,c   Stehle, Jean Christophe ^a   Rausch, Thierry ^a   Faes Van't Hull, Eveline ^a   Bieler, Grégory ^a,c   Alghisi, Gian Carlo ^a   Schwendener, Reto ^d   Andrejevic Blant, Snezana ^a   Mirimanoff, René Olivier ^a   Rüegg, Curzio ^a,b,c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b EPFL   (Switzerland)

^c University of Fribourg   (Switzerland)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e MERCK KGAA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACK 2; AMN 107 AA; CLODROLIP; HYPOXIA INDUCIBLE FACTOR 1; NILOTINIB; NSC 134754; PROTEIN ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; STEM CELL FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BREAST; BREAST CANCER; CANCER CONTROL; CANCER INHIBITION; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CELL ACTIVITY; CELL LOSS; CELL TRANSFER; CHEMICAL ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; GENETIC ANALYSIS; HISTOLOGY; HYPOXEMIA; HYPOXIA; IMMOBILIZED CELL; LOADING DRUG DOSE; LUNG METASTASIS; LUNG TUMOR; LYMPHOMA; METASTASIS; METASTASIS POTENTIAL; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIATION DOSE; RISK REDUCTION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANOXIA; ANTIGENS, CD11B; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-KIT; SIGNAL TRANSDUCTION; STEM CELL FACTOR; TUMOR BURDEN;

EID: 84865074154     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3028     Document Type: Article

References (52)

1. Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1995;333:1456-61.
2. Vicini FA, Kestin L, Huang R, Martinez A. Does local recurrence affect the rate of distant metastases and survival in patients with early-stage breast carcinoma treated with breast-conserving therapy? Cancer 2003;97:910-9.
3. Vikram B, Strong EW, Shah JP, Spiro R. Failure in the neck following multimodality treatment for advanced head and neck cancer. Head Neck Surg 1984;6:724-9.
4. Milas L, Hirata H, Hunter N, Peters LJ. Effect of radiation-induced injury of tumor bed stroma on metastatic spread of murine sarcomas and carcinomas. Cancer Res 1988;48:2116-20.
5. Camplejohn RS, Penhaligon M. The tumour bed effect: a cell kinetic and histological investigation of tumours growing in irradiated mouse skin. Br J Radiol 1985;58:443-51.
6. Penhaligon M, Courtenay VD, Camplejohn RS. Tumour bed effect: hypoxic fraction of tumours growing in preirradiated beds. Int J Radiat Biol Relat Stud Phys Chem Med 1987;52:635-41.
7. Monnier Y, Farmer P, Bieler G, Imaizumi N, Sengstag T, Alghisi GC, et al. CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Res 2008;68:7323-31.
8. Rofstad EK, Mathiesen B, Henriksen K, Kindem K, Galappathi K. The tumor bed effect: increased metastatic dissemination from hypoxia-induced up-regulation of metastasis-promoting gene products. Cancer Res 2005;65:2387-96.
9. Imaizumi N, Monnier Y, Hegi M, Mirimanoff RO, Ruegg C. Radiotherapy suppresses angiogenesis in mice through TGF-betaRI/ALK5-dependent inhibition of endothelial cell sprouting. PLoS One 2010;5:e11084.
10. Ahn GO, Tseng D, Liao CH, Dorie MJ, Czechowicz A, Brown JM. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci U S A 2010;107:8363-8.
11. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941-3.
12. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53:113-7.
13. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-15.
14. Chaudary N, Hill RP. Hypoxia and metastasis in breast cancer. Breast Dis 2006;26:55-64.
15. Rofstad EK, Mathiesen B, Galappathi K. Increased metastatic dissemination in human melanoma xenografts after subcurative radiation treatment: radiation-induced increase in fraction of hypoxic cells and hypoxia-induced up-regulation of urokinase-type plasminogen activator receptor. Cancer Res 2004;64:13-8.
16. Besmer P. The kit ligand encoded at the murine Steel locus: a pleiotropic growth and differentiation factor. Curr Opin Cell Biol 1991;3:939-46.
17. Anderson DM, Williams DE, Tushinski R, Gimpel S, Eisenman J, Cannizzaro LA, et al. Alternate splicing of mRNAs encoding human mast cell growth factor and localization of the gene to chromosome 12q22-q24. Cell Growth Differ 1991;2:373-8.
18. Liu H, Chen X, Focia PJ, He X. Structural basis for stem cell factor-KIT signaling and activation of class III receptor tyrosine kinases. EMBO J 2007;26:891-901.
19. Besmer P, Manova K, Duttlinger R, Huang EJ, Packer A, Gyssler C, et al. The kit-ligand (steel factor) and its receptor c-kit/W: pleiotropic roles in gametogenesis and melanogenesis. Dev Suppl 1993:125-37.
20. Pittoni P, Piconese S, Tripodo C, Colombo MP. Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors. Oncogene 2011;30:757-69.
21. Stanulla M, Welte K, Hadam MR, Pietsch T. Coexpression of stem cell factor and its receptor c-Kit in human malignant glioma cell lines. Acta Neuropathol 1995;89:158-65.
22. Crivellato E, Nico B, Ribatti D. Mast cells and tumour angiogenesis: new insight from experimental carcinogenesis. Cancer Lett 2008;269:1-6.
23. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, BehrendtsenO, Werb Z, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999;13:1382-97.
24. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992;52:1399-405.
25. Kuonen F, Touvrey C, Laurent J, Ruegg C. Fc block treatment, dead cells exclusion, and cell aggregates discrimination concur to prevent phenotypical artifacts in the analysis of subpopulations of tumor-infiltrating CD11b(+) myelomonocytic cells. Cytometry A 2010;77:1082-90.
26. Barton M. Tables of equivalent dose in 2 Gy fractions: a simple application of the linear quadratic formula. Int J Radiat Oncol Biol Phys 1995;31:371-8.
27. Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjallman AH, Ballmer-Hofer K, Schwendener RA. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 2006;95:272-81.
28. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008;8:618-31.
29. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438:820-7.
30. Chau NM, Rogers P, Aherne W, Carroll V, Collins I, McDonald E, et al. Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors. Cancer Res 2005;65:4918-28.
31. Broudy VC. Stem cell factor and hematopoiesis. Blood 1997;90:1345-64.
32. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010;120:694-705.
33. Schernthaner GH, Hauswirth AW, Baghestanian M, Agis H, Ghannadan M, Worda C, et al. Detection of differentiation- and activationlinked cell surface antigens on cultured mast cell progenitors. Allergy 2005;60:1248-55.
34. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008;181:5791-802.
35. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007;67:4507-13.
36. Younos I, Donkor M, Hoke T, Dafferner A, Samson H, Westphal S, et al. Tumor- and organ-dependent infiltration by myeloid-derived suppressor cells. Int Immunopharmacol 2011;11:816-26.
37. Torihashi S, Nishi K, Tokutomi Y, Nishi T, Ward S, Sanders KM. Blockade of kit signaling induces transdifferentiation of interstitial cells of cajal to a smooth muscle phenotype. Gastroenterology 1999;117:140-8.
38. Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, Martiny-Baron G, et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 2010;1804:445-53.
39. Sihto H, Tynninen O, Halonen M, Puputti M, Karjalainen-Lindsberg ML, Kukko H, et al. Tumour microvessel endothelial cell KIT and stem cell factor expression in human solid tumours. Histopathology 2009;55:544-53.
40. Lefevre G, Glotin AL, Calipel A, Mouriaux F, Tran T, Kherrouche Z, et al. Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis. J Biol Chem 2004;279:31769-79.
41. Sun L, Hui AM, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 2006;9:287-300.
42. Huang B, Lei Z, Zhang GM, Li D, Song C, Li B, et al. SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood 2008;112:1269-79.
43. De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005;8:211-26.
44. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008;222:162-79.
45. Zumsteg A, Baeriswyl V, Imaizumi N, Schwendener R, Ruegg C, Christofori G. Myeloid cells contribute to tumor lymphangiogenesis. PLoS One 2009;4:e7067.
46. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008;13:23-35.
47. Lewis JS, Landers RJ, Underwood JC, Harris AL, Lewis CE. Expression of vascular endothelial growth factor by macrophages is upregulated in poorly vascularized areas of breast carcinomas. J Pathol 2000;192:150-8.
48. Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegue E, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008;13:206-20.
49. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007;131:463-75.
50. Lennartsson J, Ronnstrand L. The stem cell factor receptor/c-Kit as a drug target in cancer. Curr Cancer Drug Targets 2006;6:65-75.
51. Liegl-Atzwanger B, Fletcher JA, Fletcher CD. Gastrointestinal stromal tumors. Virchows Arch 2010;456:111-27.
52. Smalley KS, Sondak VK, Weber JS. c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histol Histopathol 2009;24:643-50.